H-M,
1. Hostastock got his MJ-suitor from the following paragraph at the bottom of page 27 of the proxy materials:
On October 5, 2016, a broker acting on behalf of a medical marijuana company (“Company B”) presented an unsolicited letter of intent to acquire the Company. On October 6, 2016, Kyle Winther had a telephone conference with the broker to discuss the letter of intent.
2. I have greatly enjoyed your presence on this board, especially the advanced grammar lesson pertaining to disjuncts. It was amusing, and hopefully to be profitable, for the gang here to learn from the proxy material that any fruits of the Magnavape litigation would be additive to the deal with shareholders.
3. As a total aside, you reminded me of my favorite legal moment during my last career years as a federal health care regulator. As I was being prepped by somebody from the Regional HHS Office of General Counsel about my upcoming one moment of fame on the witness stand where I would testify that Blue Cross of North Dakota is a "financial intermediary" for the Medicare program, I was cautioned not to go into my typical story-telling mode, but rather just to answer very simply the question put to me. I am a literal kind of person, so when I was asked on the stand "can you state your name?" I came much too close to responding "yes."
Good day to all, and I hope that, going with your simile of "like a dog on a bone," through your professional efforts there will a goodly portion of meat added to that bone. Overall, the flavor I am tasting is that company management was out-maneuvered at some key turns of both the manufacturing and purchase-transaction processes, and it's above my pay grade to know what the benchmark is for legal liability to enter the picture. But that's for private discussion among the potential plaintiffs, not for here.
